Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen

Vemurafenib is a BRAF kinase inhibitor (BRAFi) that is used to treat melanoma patients harboring the constitutively active BRAF-V600E mutation. However, after a few months of treatment patients often develop resistance to vemurafenib leading to disease progression. Sequence analysis of drug-resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Goh, Corinna Jie Hui, Wong, Jin Huei, El Farran, Chadi, Tan, Ban Xiong, Coffill, Cynthia R, Loh, Yuin-Hain, Lane, David, Arumugam, Prakash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Mutant Screen Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8022920/
https://www.ncbi.nlm.nih.gov/pubmed/33604667
http://dx.doi.org/10.1093/g3journal/jkaa069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8022920/
https://www.ncbi.nlm.nih.gov/pubmed/33604667
http://dx.doi.org/10.1093/g3journal/jkaa069

Ejemplares similares